Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Rating the intelligibility of dysarthic speech amongst people with Parkinson's Disease: a comparison of trained and untrained listeners.

Smith CH, Patel S, Woolley RL, Brady MC, Rick CE, Halfpenny R, Rontiris A, Knox-Smith L, Dowling F, Clarke CE, Au P, Ives N, Wheatley K, Sackley CM.

Clin Linguist Phon. 2019;33(10-11):1063-1070. doi: 10.1080/02699206.2019.1604806. Epub 2019 Apr 29.


Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson's disease: a pilot randomised controlled trial (PD COMM pilot).

Sackley CM, Smith CH, Rick CE, Brady MC, Ives N, Patel S, Woolley R, Dowling F, Patel R, Roberts H, Jowett S, Wheatley K, Kelly D, Sands G, Clarke CE; PD COMM Pilot Collaborative Group.

Pilot Feasibility Stud. 2018 Jan 10;4:30. doi: 10.1186/s40814-017-0222-z. eCollection 2018.


Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).

Clarke CE, Patel S, Ives N, Rick CE, Woolley R, Wheatley K, Walker MF, Zhu S, Kandiyali R, Yao G, Sackley CM.

Health Technol Assess. 2016 Aug;20(63):1-96. doi: 10.3310/hta20630.


Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial.

Clarke CE, Patel S, Ives N, Rick CE, Dowling F, Woolley R, Wheatley K, Walker MF, Sackley CM; PD REHAB Collaborative Group.

JAMA Neurol. 2016 Mar;73(3):291-9. doi: 10.1001/jamaneurol.2015.4452.


Treatment Reasons, Resource use and Costs of Hospitalisations in People with Parkinson's: Results from a Large Rct.

Xin Y, Clarke CE, Muzerengi S, Rick CE, Gray A, Gray R, Wheatley K, Ives N, McIntosh E.

Value Health. 2014 Nov;17(7):A809. doi: 10.1016/j.jval.2014.08.541. Epub 2014 Oct 26. No abstract available.


Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the gamma2 subunit of the gamma-aminobutyrate type A receptor.

Homanics GE, Harrison NL, Quinlan JJ, Krasowski MD, Rick CE, de Blas AL, Mehta AK, Kist F, Mihalek RM, Aul JJ, Firestone LL.

Neuropharmacology. 1999 Feb;38(2):253-65.


Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane.

Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE, Harrison NL.

Mol Pharmacol. 1998 Mar;53(3):530-8.


Neurosteroids act on the GABA(A) receptor at sites on the N-terminal side of the middle of TM2.

Rick CE, Ye Q, Finn SE, Harrison NL.

Neuroreport. 1998 Feb 16;9(3):379-83.


A deficit of functional GABA(A) receptors in neurons of beta 3 subunit knockout mice.

Krasowski MD, Rick CE, Harrison NL, Firestone LL, Homanics GE.

Neurosci Lett. 1998 Jan 9;240(2):81-4.


Alpha subunit isoform influences GABA(A) receptor modulation by propofol.

Krasowski MD, O'Shea SM, Rick CE, Whiting PJ, Hadingham KL, Czajkowski C, Harrison NL.

Neuropharmacology. 1997 Jul;36(7):941-9.


Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior.

Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, Harrison NL, Krasowski MD, Rick CE, Korpi ER, Mäkelä R, Brilliant MH, Hagiwara N, Ferguson C, Snyder K, Olsen RW.

Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):4143-8.


Two sulphonated dye compounds which compete for inositol 1,4, 5-trisphosphate binding to rat liver microsomes: effects on 5'-phosphatase activity.

Bootman MD, Pay GF, Rick CE, Tones MA.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1334-9. Erratum in: Biochem Biophys Res Commun 1990 Apr 16;168(1):387.


Supplemental Content

Support Center